A Phase 2 Multi-centre Randomized Double-blind Placebo-controlled Parallel Group Study to Examine the Effects of 24 Weeks Tezepelumab 210 mg sc q4wks on Methacholine Airway Hyperresponsiveness in Participants With Mild Allergic Asthma
Latest Information Update: 27 Feb 2023
At a glance
- Drugs Tezepelumab (Primary)
- Indications Allergic asthma
- Focus Therapeutic Use
Most Recent Events
- 27 Feb 2023 New trial record